RxDoctor Payments DataLook up a doctor →

Ali Anaim, DPM

Foot & Ankle Surgery · Philadelphia, PANPI 1891733499

Payments from drug & device makers

$16,693in general payments, 2019–2025

Across 353 payments — averaging $47.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • In2bones USA, LLC$3K
  • Smith+Nephew$3K
  • Stryker$2K
  • Paladin Technology Solutions$955
  • Organogenesis Inc.$846
  • Kerecis Limited$787
  • plus $6K from 52 others

What the payments were for

  • Speaking & faculty fees$2,00012%
  • Travel & lodging$1,4789%
  • Food & beverage$12,46975%
  • Education$6294%
  • Entertainment$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,693 in reported general payments places this provider in the 85th percentile of 575 foot & ankle surgery providers in Pennsylvania.

See all foot & ankle surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$371,663
Medicare patients
150
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.86$55,694
Ciclopirox239$9,955
CiclopiroxCiclopirox Olamine547$8,823
Ammonium Lactate418$6,974
Diclofenac Sodium120$2,845
Fluocinonide48$2,286
Mupirocin166$1,107
Omeprazole177$915
Gabapentin130$757
Meloxicam188$729
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav46$566
Ketoconazole20$416
Cephalexin20$377
Pregabalin31$299
Clindamycin Hcl35$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$2,976$55,69486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 575 foot & ankle surgery providers in Pennsylvania.

Other foot & ankle surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →